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Purpose: To measure the impact of a diabetes and cardiovascular risk factors program 
 implemented in a social security institution upon short- and long-term clinical/metabolic 
 outcomes and costs of care.
Methods: Observational longitudinal cohort analysis of clinical/metabolic data and resource 
use of 300 adult male and female program participants with diabetes before (baseline) and 
1 and 3 years after implementation of the program. Data were obtained from clinical records 
(Qualidiab) and the administration’s database.
Results: The implementation of the program in “real world” conditions resulted in an  immediate 
and sustainable improvement of the quality of care provided to people with diabetes incorpo-
rated therein. We also recorded a more appropriate oral therapy prescription for hyperglycemia 
and cardiovascular risk factors (CVRFs), as well as a decrease of events related to chronic 
 complications. This improvement was associated with an increased use of diagnostic and thera-
peutic resources, particularly those related to pharmacy prescriptions, not specifically used for 
the control of hyperglycemia and other CVRFs.
Conclusion: The implementation of a diabetes program in real-world conditions results in a 
significant short- and long-term improvement of the quality of care provided to people with 
diabetes and other CVRFs, but simultaneously increased the use of resources and the cost of 
diagnostic and therapeutic practices. Since controlled studies have shown improvement in quality 
of care without increasing costs, our results suggest the need to include management-control 
strategies in these programs for appropriate medical and administrative feedback to ensure the 
simultaneous improvement of clinical outcomes and optimization of the use of resources.
Keywords: management, program evaluation, chronic diseases, diabetes
Introduction
Diabetes is a costly and ever-increasing health problem frequently associated with the 
development of chronic complications that result in a heavy socioeconomic burden for 
the health system and society overall.1–3 Cardiovascular complications represent the 
major cause of diabetes morbidity, mortality, and costs, and they can be significantly 
reduced by appropriate control of blood glucose and associated cardiovascular risk 
factors (CVRFs).1,4–10 However, prevention strategies have not been widely incor-
porated into daily clinical practice,11 and the care provided to people with diabetes 
is frequently far from optimal.5,12–16 Consequently, the care of these people usually 
consumes 5%–10% of health budgets.17
This situation could be improved by the integration and coordination of interdisci-
plinary teams in a structured diabetes program capable of optimizing both  effectiveness 
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and resource use. Such an assertion is supported by the 
significant improvement in several clinical and metabolic 
indicators of quality of care of people with type 2 diabetes and 
the decrease in direct medical costs observed after the imple-
mentation of Program for the Prevention, Care and Treat-
ment of People with Diabetes (PROPAT) in Argentina18,19 
and similar initiatives in other countries. PROPAT was a 
controlled study, but there is no evidence of the efficacy of 
this type of program in “real world” conditions. Therefore, 
we considered it would be important to test the effectiveness 
of a similar program but implemented in a social security 
health institution of Argentina.
The Argentine health-care system includes three indepen-
dent sectors: public, social security, and private (prepaid).20 
OSPERYH (Obra Social del Personal de Edificios de Renta y 
Horizontal) is a health-management organization that belongs 
to the social security sector. It is organized at national level 
and provides health coverage to nearly 100,000 people in the 
city of Buenos Aires.
In order to obtain the information mentioned previ-
ously, in June 2005 we implemented a diabetes program in 
OSPERYH (DPO) that modified the traditional care system 
of the organization. At that time, general practitioners 
were responsible for the control and treatment of people 
with diabetes and the prescription of periodic controls by 
specialists. The organization had neither specific procedure 
manuals, medical processes, nor standardized administrative 
 procedures. Furthermore, data from clinical practices, labora-
tory tests, drug prescriptions, and hospitalization events were 
partially recorded at different areas and used for economic 
and legal purposes rather than as a suitable tool to control the 
quality of care provided to patients. Equity of health cover-
age was poor, since it was determined by a national law that 
guarantees the provision of “baseline” care instead of care 
plans meeting real individual needs. Additionally, there were 
no diabetes-education programs for physicians or patients, 
with a negligible participation of the latter in control and 
treatment of their disease.
The DPO introduced the systematization of processes 
and procedures of care, from the enrollment of participants 
into the program up to drug supply. In this context, the DPO 
implemented standards of care, control and treatment, a 
yearly schedule of visits to the physician’s office, and the per-
formance of special practices (electrocardiogram, endoscopy, 
ergometry, spirometry, fluxometry, holter monitor, radiogra-
phy, tomography), and laboratory tests based on international 
guidelines for good clinical practice. It also incorporated a 
periodic record of clinical, metabolic, and therapeutic data 
and the provision of a personalized check-book to facilitate 
patient access to clinical care, laboratory tests and different 
special practices, drugs, and devices. This record system 
also served to identify the type and amount of resource 
consumption. All these practices and procedures, as well as 
the prescription of drugs and supplies for self-control, had 
100% coverage. Additionally, the DPO provided diabetes 
education to physicians and people with diabetes, promot-
ing the active participation of the latter in the control and 
treatment of their disease. Finally, the DPO implemented 
a system for the continuous monitoring of diabetes care, 
clinical, metabolic, therapeutic, and economic indicators, 
and program performance.
In this study, we report the immediate and long-term clini-
cal, metabolic, and budget impact of the DPO implemented 
in noncontrolled conditions in OSPERYH.
Materials and methods
Design
The study represents an observational and longitudinal pro-
spective cohort analysis of people with diabetes. We analyzed 
the performance of procedures, many clinical, metabolic, and 
therapeutic indicators of quality of care, the rate of resource 
utilization and associated costs before (baseline) and at 1 and 
3 years after implementation of the DPO. For every study 
period, data were recorded for 12 months. We simultaneously 
evaluated several OSPERYH indicators of the health-care 
management process.
The study design and its procedures were approved by the 
Central Advisory Committee on Bioethics of the National 
University of La Plata.
Population
People with diabetes were invited to participate in the 
study by their doctors during their periodic controls, and 
were incorporated into the DPO after signing the pertinent 
informed consent. Through this procedure, 1366 affiliates 
were incorporated into the DPO in the year 2006; three years 
later, 300 affiliates remained in the program. No significant 
differences were recorded between completers and dropouts 
from the point of view of their demographic, clinical, or 
metabolic characteristics (Table 1). Consequently, we only 
included and compared data from the 300 patients at baseline 
and 1 and 3 years after DPO implementation.
Diabetes diagnosis was made using the Latin American 
Diabetes Association criteria,21 while obesity,  hypertension, 
and dyslipidemia were diagnosed using the American 
 Diabetes Association,22,23 the Joint National Committee on 
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Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure,24 and the National Cholesterol  Education 
Program25 criteria, respectively. Cardiovascular risk was 
assessed with the Second Joint European Task Force 
guidelines,26 while the degree of metabolic control was deter-
mined using the Latin American Diabetes Association21 and 
the International Diabetes Federation27 guidelines.
Inclusion and exclusion criteria
We only incorporated adult male and female OSPERYH 
participants (age $18 years) from the city of Buenos Aires, 
Argentina, with diabetes, who had been controlled for 
their disease for at least 2 years and regularly attended the 
DPO. People with mental illnesses that affected behavior, 
alcohol or drug abuse, or who refused to sign the informed 
consent were excluded from the study.
Data-collection instruments
The annual and semiannual Qualidiab data-collection 
forms28 and an annual personalized check-book of medical 
and laboratory tests and drug prescription were used to mea-
sure the following variables: demographic data, diabetes-
education indicators, performance of diagnostic/control 
procedures, presence of acute and chronic complications 
(micro/ macrovascular complications), hospitalization rate, 
and absenteeism. We also recorded clinical and therapeutic 
indicators of degree of control of hyperglycemia, associated 
CVRFs, other health conditions, and costs of care (annual 
consumption of diagnostic and therapeutic resources). All 
the data recorded were anonymously stored at CENEXA 
(Center of Experimental and Applied Endocrinology) in a 
database using SQLyog (Webyog, Santa Clara, CA, USA) 
software.
Data analysis
The effectiveness of the intervention was measured through 
changes in: (1) glycated hemoglobin (HbA
1c
) values, show-
ing the degree of metabolic control during the last 3 months; 
(2) fasting blood glucose (FBG) levels; (3) serum lipid profile 
(total cholesterol and triglyceride levels); and (4) average 
resource consumption, percentage of performance, and 
per capita direct medical costs (hospitalizations, medical 
practices, laboratory tests, visits to the doctor’s office, and 
consumption of drugs and devices for self-monitoring blood 
Table 1 Clinical characteristics and use of resources of the selected sample versus patients who dropped out of the diabetes program 
in OSPERYH
Baseline P-value
Study sample 
n = 300
Dropouts 
n = 1,066
Mean Proportions
Mean ± SD (n) Mean ± SD (n)
Clinical/metabolic indicators
BMI (kg/m2) 30.5 ± 5.6 (287) 30.3 ± 5.5 (990) 0.587 –
SBP (mmHg) 131 ± 16 (272) 133 ± 17 (941) 0.087 –
DBP (mmHg) 81 ± 11 (271) 81 ± 11 (938) 0.890 –
FBG (mg/dL) 126 ± 45 (96) 139 ± 57 (405) ,0.05 –
HbA1c (%) 7.9 ± 2.1 (133) 8.2 ± 2.2 (498) 0.159 –
Creatinine (mg/dL) 0.9 ± 0.2 (176) 0.9 ± 0.3 (572) 0.271 –
Proteinuria (mg/dL) 6 ± 3 (40) 6 ± 4 (132) 0.782 –
Total cholesterol (mg/dL) 205 ± 44 (233) 209 ± 45 (821) 0.231 –
HDL-chol (mg/dL) 
 Women 54 ± 35 (74) 53 ± 19 (106) 0.734 –
 Men 50 ± 31 (107) 49 ± 15 (142) 0.657 –
LDL-chol (mg/dL) 119 ± 38 (162) 125 ± 37 (572) 0.073 –
Triglycerides (mg/dL) 182 ± 99 (212) 181 ± 104 (733) 0.901 –
Average consumption, percentage of performance*
Hospitalizations 11.7 ± 9.7 [5.7, 3–9] 10.2 ± 9.8 [7.04, 6–9] 0.595 0.670
Visits to the doctor’s office 9.3 ± 6.6 [98, 96–99] 9.3 ± 7.4 [98, 97–99] 0.966 0.973
Practices 1.9 ± 2.1 [32, 27–37] 1.7 ± 1.7 [28, 26–31] 0.342 0.171
Laboratory tests 15.5 ± 10.0 [90, 87–94] 16.4 ± 10.5 [89, 87–91] 0.189 0.324
Pharmacy 12.8 ± 15.6 [51, 45–57] 15.8 ± 20.5 [43, 42–48] 0.098 0.013
Notes: *Values in brackets: %, 95% CI.
Abbreviations: OSPERYH, Obra Social del Personal de Edificios de Renta y Horizontal; SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; HDL-chol, high-density lipoprotein cholesterol; LDL-chol, low-density lipoprotein 
cholesterol; CI, confidence interval.
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glucose). All indicators from the 300 selected affiliates were 
measured at baseline and 1 and 3 years after implementation 
of the DPO.
Cost-of-care analysis included (1) resource identifica-
tion (units of measure and quantities), (2) choice of analysis 
perspective (social security subsector), inclusion of relevant 
resources and unit-cost identification, and (3) estimation 
of total and incremental costs. For the analysis we used the 
CostIt version 4.4 (WHO, Geneva, Switzerland) software 
and the WHO-CHOICE methodology proposed by WHO.29 
Budget impact was evaluated comparing the noninterven-
tion (baseline) versus the intervention (1- and 3-year) sce-
narios. The unit cost of resources was obtained from values 
of the Nomenclador Asistencial Nacional, Nomenclador 
Bioquímico Único, and Nomenclador Agremiación Médica 
Platense. All costs are expressed in Argentine pesos (AR$) for 
the year 2011.
Descriptive statistics are presented as percentages with 95% 
confidence intervals (CIs) and means ± standard  deviation. 
Chi-squared testing was performed for all proportions, and 
Student’s t-test was used for all means. The significance level 
was set at P , 0.05. All statistical analyses were performed 
with the Epi-Info 6.4 (CDC, Atlanta, GA, USA) statistical 
package or SPSS 15.0 (IBM, Armonk, NY, USA).
Results
Population characteristics
Fifty-eight percent of the patients included in the analysis 
were men, with an average age of 55 years; 8% and 92% of 
them had type 1 and type 2 diabetes, respectively. Except for 
FBG, no differences were recorded at any of the parameters 
tested between completers and dropouts (Table 1).
Clinical and metabolic impact
Procedure performance increased significantly 1 year after 
DPO implementation and continued on an upward trend 
thereafter, except for body mass index (BMI) and blood 
pressure control, which declined to baseline values. It is 
worth noting that the performance of these two procedures 
was already high at baseline (90% and 91%, respectively; 
Table 2).
Habits
At baseline, 19% of the sample population consumed 
tobacco, 21% consumed alcohol, 67% followed a meal plan, 
and 35% were physically active. These figures did not change 
significantly 1 and 3 years after DPO implementation, except 
for a slight increase in physical activity (38%).
Table 2 Changes in the performance of control procedures
Parameter Baseline 
n = 300
1 year 
n = 300
3 years 
n = 300
% (95% CI) % (95% CI) % (95% CI)
Foot examination* 51 (44–78) 92 (85–96)a 96 (90–98)a
Eye examination† 46 (38–54) 72 (64–79)a 74 (65–81)a
BMI 90 (86–93) 99 (97–100)a 92 (88–95)b
Blood pressure 91 (87–94) 96 (93–98)a 92 (88–95)b
FBG 32 (27–38) 65 (59–70)a 91 (87–94)a,b
HbA1c 44 (38–50) 77 (72–81)
a 81 (76–85)a
Creatinine 59 (53–64) 79 (74–83)a 79 (74–83)a
Total cholesterol 78 (73–82) 77 (72–81) 85 (80–89)a,b
HDL-chol 60 (54–66) 76 (71–80)a 83 (78–87)a
LDL-chol 54 (48–60) 71 (66–76)a 81 (76–85)a,b
Triglycerides 71 (65–76) 83 (79–87)a 83 (78–87)a
Microalbuminuria 3 (1–6) 4 (2–7) 12 (9–16)a,b
Notes: *Baseline n = 210, 1 year n = 98, 3 years n = 117; †baseline n = 170, 1 year 
n = 144, 3 years n = 118; acompared to baseline, P , 0.05; bcompared to 1 year, P , 0.05.
Abbreviations: CI, confidence interval; BMI, body mass index; FBG, fasting blood 
glucose; HbA1c, glycated hemoglobin; HDL-chol, high-density lipoprotein cholesterol; 
LDL-chol, low-density lipoprotein cholesterol.
Clinical and metabolic parameters
Most of the clinical and metabolic parameters improved 
significantly 1 year after implementation of the DPO, with 
significant decreases of systolic and diastolic blood  pressure, 
HbA
1c
, and serum triglyceride levels (Table 3). These 
improvements were still present 3 years after DPO imple-
mentation, except those related to glucose metabolism (FBG 
and HbA
1c
), whose values returned almost to those recorded 
at baseline. In the case of triglyceride levels, the improvement 
recorded 1 year after was sustained and became even larger 
3 years after program implementation.
Related to these changes, we also observed a significant 
beneficial effect of the DPO on the percentage of people 
attaining target treatment values in several parameters 
(Table 4). One year after implementation, there was a sig-
nificant increase in the percentage of people at target blood 
pressure, serum total cholesterol, and triglyceride levels; these 
effects were still evident 3 years later. Conversely, no signifi-
cant changes were observed in BMI, FBG, or HbA
1c
 values.
Treatment characteristics
At baseline, 94% of patients were on oral antidiabetic drugs 
(56% of them were treated with only one drug), while 14% 
received insulin (Table 5). One year after implementation, 
we detected a significant increase only in the percentage of 
people treated for dyslipidemia. Conversely, 3 years after 
DPO implementation, a significant treatment increment was 
observed in every condition tested, with the only exception 
being insulin administration, which showed an increasing 
but not statistically significant trend.
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Table 3 Clinical/metabolic indicators
Parameter Baseline 1 year 3 years
Mean ± SD (n) Mean ± SD (n) Mean ± SD (n)
BMI (kg/m2) 30.5 ± 5.6 (287) 30.4 ± 5.5 (264) 30.4 ± 5.4 (275)
SBP (mmHg) 131 ± 16 (272) 127 ± 13.3 (257)a 128 ± 14 (276)a
DBP (mmHg) 81 ± 11 (271) 77,9 ± 10 (256)a 79 ± 9 (277)a
FBG (mg/dL) 126 ± 45 (96) 118 ± 38 (187) 132 ± 40 (277)b
HbA1c (%) 7.9 ± 2.1 (133) 7.3 ± 1.6 (212)a 7.7 ± 1.7 (244)
Creatinine (mg/dL) 0.9 ± 0.2 (176) 0.9 ± 0.2 (219) 0.8 ± 0.4 (236)b
Proteinuria (mg/dL) 6 ± 3 (40) 3 ± 4 (40) 1 ± 6 (152)a,b
Total cholesterol (mg/dL) 205 ± 44 (233) 201 ± 40,8 (233) 197 ± 42 (256)a
HDL-chol (mg/dL) 
 Women 54 ± 35 (107) 54 ± 15 (85) 52 ± 58 (106)
 Men 50 ± 31 (74) 48 ± 11 (121) 46 ± 17 (142)
LDL-chol (mg/dL) 119 ± 38 (162) 119 ± 36 (194) 121 ± 37 (243)
Triglycerides (mg/dL) 182 ± 99 (212) 159 ± 92 (226)a 140 ± 74 (250)a,b
Notes: aCompared to baseline, P , 0.05; bcompared to 1 year, P , 0.05.
Abbreviations: SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; HbA1c, glycated 
hemoglobin; HDL-chol, high-density lipoprotein cholesterol; LDL-chol, low-density lipoprotein cholesterol.
Table 4 Percentage of people who achieved treatment target values of clinical and metabolic parameters
Parameter Baseline 1 year 3 years
% [95% CI] (n) % [95% CI] (n) % [95% CI] (n)
BMI , 25 kg/m2 15 [11–20] (287) 15 [11–19] (299) 13 [9–17] (275)
SBP , 130 and DBP , 85 mmHg 38 [33–44] (272) 48 [42–54] (287)a 49 [43–55] (277)a
FBG , 100 mg/dL 39 [29–49] (96) 31 [25–38] (194) 30 [25–36] (273)
HbA1c , 7% 40 [32–49] (133) 46 [40–53] (231) 41 [35–47] (244)
Total cholesterol ,200 mg/dL 48 [42–55] (233) 48 [42–54] (262) 56 [50–62] (255)a
Triglycerides ,150 mg/dL 46 [39–53] (212) 57 [51–63] (250)a 64 [58–70] (250)a
Notes: aCompared to baseline, P , 0.05; compared to 1 year, P , 0.05.
Abbreviations: CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; HbA1c, glycated 
hemoglobin.
Related to this, we observed a marked tendency to use 
combined therapy rather than monotherapy, particularly in 
the cases of hyperglycemia and high blood pressure.
Complication-related events
The number of people with at least one event related to 
chronic complications showed a nonsignificant decrease 
from 45% to 42% 3 years after DPO implementation. These 
complication-related events included microangiopathic 
(blindness, chronic renal failure with replacement therapy, 
peripheral neuropathy, nephropathy, orthostatic hypotension, 
and erectile dysfunction) and macroangiopathic (acute myo-
cardial infarction, stroke, angor, lower-limb claudication, and 
revascularization) complications.
Economic impact
The percentage of people who had at least one hospitalization 
event increased significantly 1 year after implementation of the 
DPO, but it was no longer observed 3 years after implementa-
tion (Table 6). The same trend was recorded in people who per-
formed at least one special practice, but in this case the change 
was still evident 3 years later.  Laboratory test performance 
did not change significantly 1 year after implementation, but 
it increased significantly 3 years after implementation.
The average number of visits to the doctor’s office  (either 
clinicians or specialists) increased significantly 1 year 
after implementation and remained high 3 years later; this 
increase was associated with a significant increase in costs 
in both study periods. However, visits specifically related to 
diabetes and CVRFs (medical clinic, nutrition, cardiology, 
and diabetology) increased less than those due to unrelated 
causes (43% and 71%, respectively).
At baseline, the annual per capita cost was AR$4,657 
and had the following distribution: hospitalization events, 
59%; visits to the doctor’s office, 18%; pharmacy, 16%; 
laboratory test, 12%; medical practices, 3% (Table 6). This 
cost increased at the other two study points (AR$7,139 and 
AR$8,437 1 year and 3 years later, respectively), having 
an uneven distribution: hospitalizations, 9.5%; visits to the 
 doctor’s office, 48%; pharmacy, 432%. Interestingly, the high-
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Table 5 Type of diabetes and CVRF treatment
Parameter Baseline 1 year 3 years
% [95% CI] (n) % [95% CI] (n) % [95% CI] (n)
OADs 94 [90–97] (237) 93 [90–96] (265) 97 [94–99] (238)b
 Monotherapy 56 [49–62] 49 [42–55] 40 [34–47]a,b
 Combined therapy ($2 drugs) 44 [38–51] 51 [45–58] 60 [53–66]a,b
Insulin 14 [11–19] (300) 16 [12–20] (300) 18 [14–23] (300)
Hypertension 68 [62–74] (242) 75 [69–80] (256) 75 [70–80] (277)
 Monotherapy 65 [58–73] 63 [56–70] 52 [46–60]a,b
 Combined therapy ($2 drugs) 35 [27–42] 37 [30–44] 48 [41–54]a,b
Dyslipidemia 39 [33–46] (224) 48 [42–55] (231)a 54 [48–61] (261)a
 Monotherapy 92 [84–96] 97 [93–99] 91 [85–95]b
 Combined therapy ($2 drugs) 8 [4–16] 3 [1–7] 9 [5–15]b
Notes: aCompared to baseline, P , 0.05; bcompared to 1 year, P , 0.05.
Abbreviations: CVRF, cardiovascular risk factor; CI, confidence interval; OADs, oral antidiabetic drugs.
Table 6 Average consumption, percentage of performance, and per capita cost in local currency (AR$)
Parameter Cost per capita
Baseline 1 year 3 years
Mean ± SD (%) (AR$) Mean ± SD (%) (AR$) Mean ± SD (%) (AR$)
Hospitalizations* 11.7 ± 9.7 2,528 9 ± 10.6 1,944 12.8 ± 11.2 2,768
(5.7) [3–9] (11.4) [4–9]a (7.3) [5–11]
Practices* 1.9 ± 2.1 116 1.9 ± 1.6 128 1.8 ± 1.9 110
(32) [27–37] (49) [44–55]a (37) [32–43]b
Laboratory tests* 15.5 ± 10.0 567 15.5 ± 8.1 542 18.8 ± 10.3a,b 759
(91) [87–94] (94) [90–96] (96) [9–98]a
Visits to the  
doctor’s office*
9.3 ± 6.6 752 13.5 ± 7.9a 1,095 13.7 ± 7.9a 1,110
(98) [96–99] (96) [94–98] (100) [98–100]a,b
Diabetes and CVRF 7.0 ± 4.7 577 10.6 ± 4.9 248 10.0 ± 4.8a 815
Other 2.1 ± 3.3 175 4.6 ± 4.4 847 3.6 ± 5.0a 295
Pharmacy* 12.8 ± 15.6 694 55.6 ± 31.6a 3,430 54.1 ± 29a 3,690
(51) [45–57] (93) [89–95]a (97) [95–98]a,b
Dyslipidemia 1.8 ± 1.4 37 4.3 ± 3.4 223 3.6 ± 2.8a 207
Diabetes 4.1 ± 4.7 149 13.6 ± 8.8 874 12.0 ± 7.6a 1,078
Hypertension 3.2 ± 3.9 88 9.0 ± 6.9 320 9.5 ± 7.3a 356
Other drugs and supplies 7.1 ± 8.0 421 26.5 ± 15.2 2,012 25.9 ± 14.9a 2,049
Total  4,657  7,139  8,437
Notes: *Between parentheses percentage of people who had at least one: hospitalization; specialized practice; laboratory practice; visit to the doctors’ office; drug to treat 
diabetes, hypertension or dyslipidemia between brackets, 95% CI; n = 300; acompared to baseline, P , 0.05; bcompared to 1 year, P , 0.05.
Abbreviations: CVRF, cardiovascular risk factor; CI, confidence interval; AR$, Argentine pesos.
est increase in visits to the doctor’s office corresponded with 
unrelated causes (68%) rather than those related to diabetes 
and CVRFs (41%).
The pharmacy per capita cost increased significantly 
(almost fivefold) from baseline to the other two observational 
periods (drug and supply group distribution: diabetes, 21%; 
dyslipidemia, 37%; hypertension, 13%; other pathologies, 
61%). Such distribution changed at the two other post-DPO 
implementation periods, the largest being that related to other 
pathologies (56%), followed by diabetes (29%), hypertension 
(10%), and dyslipidemia (6%).
Discussion
Reported evidence shows that implementation of controlled 
diabetes prevention and treatment programs can simultane-
ously improve quality of care and decrease direct medical 
costs. In our country, the implementation of PROPAT, an 
example of this type of controlled program, also showed such 
a dual beneficial impact.18,19
Implementation of the DPO under real-world conditions 
clearly demonstrated a significant improvement in the per-
formance of most medical procedures and laboratory tests 
1 year later; in most cases, the effect was sustained 3 years 
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later (Table 2). These data represent indirect evidence of 
quality-of-care improvement.30 Interestingly, despite the 
significant increase in procedure performance, none of the 
values reached 100% either 1 or 3 years after DPO imple-
mentation, even when costs were fully covered by the DPO. 
Similar data were recorded with PROPAT,18,19 thus showing 
how difficult it is to remove long-established inappropriate 
routines.
The DPO data also showed a significant improvement in 
most of the clinical/metabolic parameters evaluated 1 year 
after its implementation; though of a lower magnitude, these 
changes were comparable to those recorded in PROPAT.18,19 
It can be argued that the small magnitude of improvement in 
some parameters could not have clinical significance, but they 
were however associated with a significant decrease in the 
number of events related to both micro- and macroangiopathic 
complications. Such association does not mean that chronic 
complications were reversed; rather, that the intervention was 
sufficient to prevent the development of complication-related 
events. The facts that every 10% decrease in HbA
1c
 reduces 
the risk of developing microalbuminuria (20%), retinopathy 
(56%), and its progression (64%),31 and that a 10 mmHg 
decrease in blood pressure also reduces the development of 
such complication-related events,32 would account for our 
current data. It should be noted that the beneficial impact 
of the DPO remained constant after the 3-year implementa-
tion, except for FBG and HbA
1c
 levels. Moreover, further 
improvement was observed in creatinine, total cholesterol, 
and triglyceride levels during the last study period.
Since the aforementioned favorable changes were not 
accompanied by similar changes in the percentage of people 
with overweight/obesity, we could assume that improve-
ments in care quality were more related to increases in drug 
 prescription/consumption than to the adoption of healthy 
habits. The fact that implementation of the DPO induced a 
significant and sustained increase in overall drug consump-
tion and a shift from monotherapy towards combined therapy 
for the control of hyperglycemia, blood pressure, and dys-
lipidemia lends support to this assumption.
The estimation of total medical costs showed that unlike 
PROPAT, where the per capita cost of care decreased 
significantly,18,19 it increased by 81% after implementation 
of the DPO. This increase was accompanied by a change in 
cost composition at the two other study periods: while at 
baseline, the highest percentage corresponded to hospitaliza-
tions, 1 and 3 years after implementation the predominant 
position was occupied by drug costs. The use of combined 
therapy rather than monotherapy to control hyperglycemia 
and associated CVRFs, as well as the increase in insulin 
prescription that demands a larger use of strips for self-
monitoring blood glucose control, would explain the change 
in cost composition. This fact would also suggest that the 
DPO promoted a transfer of economic resources from reha-
bilitation to prevention practices.
On the other hand, the increased use of resources (number 
of visits to the doctor’s office and pharmacy consumption; 
Table 5) was not caused by the control and treatment of 
diabetes or the associated CVRFs. One possible explanation 
is that the higher number of monitoring and laboratory tests 
performed probably facilitated the identification of other 
dysfunctions not perceived previously and therefore not 
treated (Table 4).
Altogether, our data suggest that outcomes of controlled 
and real-world diabetes programs are not fully the same: while 
national and international evidence has proved that the imple-
mentation of the former improves quality of care and simul-
taneously reduces costs,18,33–36 the latter, in this case the DPO, 
improves quality of care but increases costs  significantly. 
This dissociation could be ascribed to an inappropriate 
management and control of the program’s implementation, 
which allowed an irrational use of resources, namely a higher 
number of laboratory tests and drug prescriptions and a higher 
doctor/specialist visit rate. Reported evidence has shown that 
this undesirable side effect can be avoided by implementing 
control mechanisms to optimize the use of resources.16,31 These 
mechanisms, automatically included in controlled studies, are 
not necessarily present in real-world trials. One indirect piece 
of evidence that this was the case in this study was the high 
patient dropout rate observed in the DPO.
The role of program management is frequently under-
scored, as shown by the fact that specific indicators are not 
easily identified in the evaluation process. We must admit, 
however, that implementation of careful planning to ensure 
a fluid interaction among key members of the institution, 
program managers, and health care professionals is not an 
easy task. In this regard, efficient management-control strate-
gies should include audits of the medical and administrative 
processes at every step of the program’s implementation, ie, 
from participant enrollment, scheduled doctor’s visits, and 
practice performance up to drug supply. In this context, one 
coordinator should take care of the program and the audit 
outcomes, and introduce adjustments in the core strategies to 
optimize medical and economic results. These adjustments 
should include activities to improve patient adherence, such 
as reminders to attend medical visits or perform laboratory 
tests. Additionally, the development of continuous diabetes-
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education activities for physicians and patients should be 
closely followed up.
In brief, our data also show that in a real-world context, 
only a suitable combination of medical and management 
strategies would simultaneously improve the quality and 
reduce the cost of care of people with diabetes.
Limitations
Despite the novelty of the data provided by our study, some 
of its characteristics limit its power and force us to interpret 
our results with caution, namely: (1) this was not a population 
study, ie, it only represents a sample of people with diabe-
tes who received care in one organization of the Argentine 
social security system and who volunteered to participate in 
the study, the latter condition certainly introducing a bias; 
(2) data are presented in a descriptive way after a simple 
statistical analysis that included the control of value distribu-
tion before applying a specific test, but without any special 
study, such as potential covariate influence; and (3) although 
several authors have shown the importance of perception of 
quality of life among patients with diabetes,37 we did not 
evaluate the issue in our study.
Beyond these limitations, the data provide a clear example 
of the difficulties of reproducing a controlled study in real-
world conditions, and consequently of obtaining identical 
outcomes; these difficulties appeared even when the study 
was implemented by the same research group and in a compa-
rable health-care setting. Further, our results serve to identify 
barriers and constraints that need to be carefully considered 
to overcome their negative influence.
Conclusion
Our results show that implementation of the DPO in real-world 
conditions results in a significant and sustainable improve-
ment of the quality of care provided to people with diabetes 
incorporated therein. This improvement was associated with 
an increased use of diagnostic and therapeutic resources, with 
a consequent negative impact upon their cost. Since controlled 
studies have shown that quality of care can be improved 
without increasing care costs, our results reinforce the need to 
include effective management control in real-world diabetes 
programs to allow appropriate medical and administrative 
feedback to ensure the simultaneous improvement of clinical 
outcomes and resource-use optimization.
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